Article
Targeting the Axl and mTOR Pathway Synergizes Immunotherapy and Chemotherapy to…
Journal of Oncology · 2022 · Ching-Ann Liu, author Horng-Jyh Harn, author Kuan-Pin Chen, author Jui-Hao Lee, author Shinn-Zong Lin, author Tsung-Lang Chiu, author Jie Mei, Academic Editor
Key facts
| Title | Targeting the Axl and mTOR Pathway Synergizes Immunotherapy and Chemotherapy to Butylidenephthalide in a Recurrent GBM |
|---|---|
| First author | Ching-Ann Liu, author Horng-Jyh Harn, author Kuan-Pin Chen, author Jui-Hao Lee, author Shinn-Zong Lin, author Tsung-Lang Chiu, author Jie Mei, Academic Editor |
| Journal | Journal of Oncology |
| Published | Mar 9, 2022 |
| DOI | 10.1155/2022/3236058 |
| Devices mentioned | K010696, K062324, K073490 |
| Product codes mentioned | CFN, JIS, MHX, MVU |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1